secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001437749-24-036630
Event type: litigation
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu settles derivative shareholder suit; court hearing Jan 13, 2025
--------------------------------------------------------------------

- Settlement approval hearing scheduled for January 13, 2025 in Delaware Chancery Court.
- Aytu to pay $250,000 in attorneys' fees and $5,000 service award to plaintiff.
- Governance enhancements include new independent board member, CEO/Chair separation, enhanced insider trading oversight.
- D&O defendants released; claims against Armistice defendants preserved with Aytu remaining neutral.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924036630/0001437749-24-036630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924036630/aytu20241203_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer